Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1)
Angela Bellini, Ulrike Pötschger, Virginie Bernard, Eve Lapouble, Sylvain Baulande, Peter F Ambros, Nathalie Auger, Klaus Beiske, Marie Bernkopf, David R Betts, Jaydutt Bhalshankar, Nick Bown, Katleen de Preter, Nathalie Clément, Valérie Combaret, Jaime Font de Mora, Sally L George, Irene Jiménez, Marta Jeison, Barbara Marques, Tommy Martinsson, Katia Mazzocco, Martina Morini, Annick Mühlethaler-Mottet, Rosa Noguera, Gaelle Pierron, Maria Rossing, Sabine Taschner-Mandl, Nadine Van Roy, Ales Vicha, Louis Chesler, Walentyna Balwierz, Victoria Castel, Martin Elliott, Per Kogner, Geneviève Laureys, Roberto Luksch, Josef Malis, Maja Popovic-Beck, Shifra Ash, Olivier Delattre, Dominique Valteau-Couanet, Deborah A Tweddle, Ruth Ladenstein, Gudrun Schleiermacher, Angela Bellini, Ulrike Pötschger, Virginie Bernard, Eve Lapouble, Sylvain Baulande, Peter F Ambros, Nathalie Auger, Klaus Beiske, Marie Bernkopf, David R Betts, Jaydutt Bhalshankar, Nick Bown, Katleen de Preter, Nathalie Clément, Valérie Combaret, Jaime Font de Mora, Sally L George, Irene Jiménez, Marta Jeison, Barbara Marques, Tommy Martinsson, Katia Mazzocco, Martina Morini, Annick Mühlethaler-Mottet, Rosa Noguera, Gaelle Pierron, Maria Rossing, Sabine Taschner-Mandl, Nadine Van Roy, Ales Vicha, Louis Chesler, Walentyna Balwierz, Victoria Castel, Martin Elliott, Per Kogner, Geneviève Laureys, Roberto Luksch, Josef Malis, Maja Popovic-Beck, Shifra Ash, Olivier Delattre, Dominique Valteau-Couanet, Deborah A Tweddle, Ruth Ladenstein, Gudrun Schleiermacher
Abstract
Purpose: In neuroblastoma (NB), the ALK receptor tyrosine kinase can be constitutively activated through activating point mutations or genomic amplification. We studied ALK genetic alterations in high-risk (HR) patients on the HR-NBL1/SIOPEN trial to determine their frequency, correlation with clinical parameters, and prognostic impact.
Materials and methods: Diagnostic tumor samples were available from 1,092 HR-NBL1/SIOPEN patients to determine ALK amplification status (n = 330), ALK mutational profile (n = 191), or both (n = 571).
Results: Genomic ALK amplification (ALKa) was detected in 4.5% of cases (41 out of 901), all except one with MYCN amplification (MNA). ALKa was associated with a significantly poorer overall survival (OS) (5-year OS: ALKa [n = 41] 28% [95% CI, 15 to 42]; no-ALKa [n = 860] 51% [95% CI, 47 to 54], [P < .001]), particularly in cases with metastatic disease. ALK mutations (ALKm) were detected at a clonal level (> 20% mutated allele fraction) in 10% of cases (76 out of 762) and at a subclonal level (mutated allele fraction 0.1%-20%) in 3.9% of patients (30 out of 762), with a strong correlation between the presence of ALKm and MNA (P < .001). Among 571 cases with known ALKa and ALKm status, a statistically significant difference in OS was observed between cases with ALKa or clonal ALKm versus subclonal ALKm or no ALK alterations (5-year OS: ALKa [n = 19], 26% [95% CI, 10 to 47], clonal ALKm [n = 65] 33% [95% CI, 21 to 44], subclonal ALKm (n = 22) 48% [95% CI, 26 to 67], and no alteration [n = 465], 51% [95% CI, 46 to 55], respectively; P = .001). Importantly, in a multivariate model, involvement of more than one metastatic compartment (hazard ratio [HR], 2.87; P < .001), ALKa (HR, 2.38; P = .004), and clonal ALKm (HR, 1.77; P = .001) were independent predictors of poor outcome.
Conclusion: Genetic alterations of ALK (clonal mutations and amplifications) in HR-NB are independent predictors of poorer survival. These data provide a rationale for integration of ALK inhibitors in upfront treatment of HR-NB with ALK alterations.
Trial registration: ClinicalTrials.gov NCT01704716.
Conflict of interest statement
Walentyna BalwierzHonoraria: Shire, Gilead Sciences, Novartis, AmgenConsulting or Advisory Role: Amgen, Novartis, Roche, TakedaTravel, Accommodations, Expenses: Jazz Pharmaceuticals, Shire, Roche, Servier Martin ElliottConsulting or Advisory Role: Bayer Dominique Valteau-CouanetConsulting or Advisory Role: EUSA PharmaResearch Funding: Orphelia PharmaPatents, Royalties, Other Intellectual Property: Royalties from Apeiron to SIOPENTravel, Accommodations, Expenses: EUSA Pharma, Jazz Pharmaceuticals Deborah A. TweddleHonoraria: Eusa PharmaTravel, Accommodations, Expenses: EUSA Pharma Ruth LadensteinHonoraria: Apeiron Biologics, Boehringer Ingelheim, EUSA PharmaConsulting or Advisory Role: Apeiron Biologics, Boehringer Ingelheim, EUSA PharmaResearch Funding: Apeiron Biologics, EUSA PharmaPatents, Royalties, Other Intellectual Property: Apeiron Biologics, EUSA PharmaExpert Testimony: Apeiron Biologics, EUSA PharmaTravel, Accommodations, Expenses: Apeiron Biologics, EUSA Pharma Gudrun SchleiermacherHonoraria: BMSResearch Funding: Bristol Myers Squibb, Pfizer, MSDavenir, RocheTravel, Accommodations, Expenses: RocheNo other potential conflicts of interest were reported.
Figures
References
- Matthay KK, Maris JM, Schleiermacher G, et al. : Neuroblastoma. Nat Rev Dis Primers 2:16078, 2016
- Holmes K, Potschger U, Pearson ADJ, et al. : Influence of surgical excision on the survival of patients with stage 4 high-risk neuroblastoma: A report from the HR-NBL1/SIOPEN study. J Clin Oncol 38:2902-2915, 2020
- Ladenstein R, Potschger U, Pearson ADJ, et al. : Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): An international, randomised, multi-arm, open-label, phase 3 trial. Lancet Oncol 18:500-514, 2017
- Ladenstein R, Potschger U, Valteau-Couanet D, et al. : Investigation of the role of dinutuximab beta-based immunotherapy in the SIOPEN high-risk neuroblastoma 1 trial (HR-NBL1). Cancers (Basel) 12:309, 2020
- Ladenstein R, Potschger U, Valteau-Couanet D, et al. : Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): A multicentre, randomised, phase 3 trial. Lancet Oncol 19:1617-1629, 2018
- Ozkaynak MF, Gilman AL, London WB, et al. : A comprehensive safety trial of chimeric antibody 14.18 with GM-CSF, IL-2, and isotretinoin in high-risk neuroblastoma patients following myeloablative therapy: Children's Oncology Group study ANBL0931. Front Immunol 9:1355, 2018
- Park JR, Kreissman SG, London WB, et al. : Effect of tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma: A randomized clinical trial. JAMA 322:746-755, 2019
- Pinto N, Naranjo A, Hibbitts E, et al. : Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG). Eur J Cancer 112:66-79, 2019
- Seeger RC, Brodeur GM, Sather H, et al. : Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313:1111-1116, 1985
- Janoueix-Lerosey I, Schleiermacher G, Michels E, et al. : Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 27:1026-1033, 2009
- Peifer M, Hertwig F, Roels F, et al. : Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature 526:700-704, 2015
- Molenaar JJ, Koster J, Zwijnenburg DA, et al. : Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 483:589-593, 2012
- Pugh TJ, Morozova O, Attiyeh EF, et al. : The genetic landscape of high-risk neuroblastoma. Nat Genet 45:279-284, 2013
- Sausen M, Leary RJ, Jones S, et al. : Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet 45:12-17, 2012
- Chen Y, Takita J, Choi YL, et al. : Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455:971-974, 2008
- George RE, Sanda T, Hanna M, et al. : Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455:975-978, 2008
- Janoueix-Lerosey I, Lequin D, Brugieres L, et al. : Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455:967-970, 2008
- Mosse YP, Laudenslager M, Longo L, et al. : Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455:930-935, 2008
- Bellini A, Bessoltane-Bentahar N, Bhalshankar J, et al. : Study of chromatin remodeling genes implicates SMARCA4 as a putative player in oncogenesis in neuroblastoma. Int J Cancer 145:2781-2791, 2019
- Javanmardi N, Fransson S, Djos A, et al. : Low frequency ALK hotspots mutations in neuroblastoma tumours detected by ultra-deep sequencing: Implications for ALK inhibitor treatment. Sci Rep 9:2199, 2019
- Combaret V, Iacono I, Bellini A, et al. : Detection of tumor ALK status in neuroblastoma patients using peripheral blood. Cancer Med 4:540-550, 2015
- Bellini A, Bernard V, Leroy Q, et al. : Deep sequencing reveals occurrence of subclonal ALK mutations in neuroblastoma at diagnosis. Clin Cancer Res 21:4913-4921, 2015
- Eleveld TF, Oldridge DA, Bernard V, et al. : Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nat Genet 47:864-871, 2015
- Bresler SC, Weiser DA, Huwe PJ, et al. : ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell 26:682-694, 2014
- Fransson S, Hansson M, Ruuth K, et al. : Intragenic anaplastic lymphoma kinase (ALK) rearrangements: Translocations as a novel mechanism of ALK activation in neuroblastoma tumors. Genes Chromosomes Cancer 54:99-109, 2015
- De Brouwer S, De Preter K, Kumps C, et al. : Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res 16:4353-4362, 2010
- Friboulet L, Li N, Katayama R, et al. : The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 4:662-673, 2014
- Guan J, Tucker ER, Wan H, et al. : The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN. Dis Model Mech 9:941-952, 2016
- Solomon BJ, Besse B, Bauer TM, et al. : Lorlatinib in patients with ALK-positive non-small-cell lung cancer: Results from a global phase 2 study. Lancet Oncol 19:1654-1667, 2018
- Ladenstein R, Potschger U, Siabalis D, et al. : Dose finding study for the use of subcutaneous recombinant interleukin-2 to augment natural killer cell numbers in an outpatient setting for stage 4 neuroblastoma after megatherapy and autologous stem-cell reinfusion. J Clin Oncol 29:441-448, 2010
- Ladenstein R, Valteau-Couanet D, Brock P, et al. : Randomized trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: The European HR-NBL1/SIOPEN study. J Clin Oncol 28:3516-3524, 2010
- Garaventa A, Poetschger U, Valteau-Couanet D, et al. : Randomized trial of two induction therapy regimens for high-risk neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group study. J Clin Oncol 39:2552-2563, 2021
- Ambros PF, Ambros IM, Brodeur GM, et al. : International consensus for neuroblastoma molecular diagnostics: Report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer 100:1471-1482, 2009
- Ambros IM, Brunner B, Aigner G, et al. : A multilocus technique for risk evaluation of patients with neuroblastoma. Clin Cancer Res 17:792-804, 2011
- Schleiermacher G, Michon J, Ribeiro A, et al. : Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study). Br J Cancer 105:1940-1948, 2011
- Schleiermacher G, Mosseri V, London WB, et al. : Segmental chromosomal alterations have prognostic impact in neuroblastoma: A report from the INRG project. Br J Cancer 107:1418-1422, 2012
- Ambros IM, Brunner C, Abbasi R, et al. : Ultra-high density SNParray in neuroblastoma molecular diagnostics. Front Oncol 4:202, 2014
- UCSC Genome Browser Home :
- Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
- Peto R, Pike MC, Armitage P, et al. : Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35:1-39, 1977
- Andersen PK, Perme MP: Pseudo-observations in survival analysis. Stat Methods Med Res 19:71-99, 2011
- Morgenstern DA, Potschger U, Moreno L, et al. : Risk stratification of high-risk metastatic neuroblastoma: A report from the HR-NBL-1/SIOPEN study. Pediatr Blood Cancer 65:e27363, 2018
- Depuydt P, Boeva V, Hocking TD, et al. : Genomic amplifications and distal 6q loss: Novel markers for poor survival in high-risk neuroblastoma patients. J Natl Cancer Inst 110:1084-1093, 2018
- Mosse YP, Lim MS, Voss SD, et al. : Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: A Children's Oncology Group phase 1 consortium study. Lancet Oncol 14:472-480, 2013
- Guan J, Fransson S, Siaw JT, et al. : Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib. Cold Spring Harb Mol Case Stud 4:a002550, 2018
- Krytska K, Ryles HT, Sano R, et al. : Crizotinib synergizes with chemotherapy in preclinical models of neuroblastoma. Clin Cancer Res 22:948-960, 2016
- Bogen D, Brunner C, Walder D, et al. : The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma. Int J Cancer 139:153-163, 2016
- Marrano P, Irwin MS, Thorner PS: Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis. Genes Chromosomes Cancer 56:28-41, 2017
- Berbegall AP, Bogen D, Potschger U, et al. : Heterogeneous MYCN amplification in neuroblastoma: A SIOP Europe Neuroblastoma study. Br J Cancer 118:1502-1512, 2018
- Turajlic S, Sottoriva A, Graham T, et al. : Resolving genetic heterogeneity in cancer. Nat Rev Genet 20:404-416, 2019
- Williams JB, Li S, Higgs EF, et al. : Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-gamma-signaling mutant cancer cells. Nat Commun 11:602, 2020
- Padovan-Merhar OM, Raman P, Ostrovnaya I, et al. : Enrichment of targetable mutations in the relapsed neuroblastoma genome. PLoS Genet 12:e1006501, 2017
- Schleiermacher G, Javanmardi N, Bernard V, et al. : Emergence of new ALK mutations at relapse of neuroblastoma. J Clin Oncol 32:2727-2734, 2014
- Chicard M, Colmet-Daage L, Clement N, et al. : Whole-exome sequencing of cell-free DNA reveals temporo-spatial heterogeneity and identifies treatment-resistant clones in neuroblastoma. Clin Cancer Res 24:939-949, 2018
- Ackermann S, Cartolano M, Hero B, et al. : A mechanistic classification of clinical phenotypes in neuroblastoma. Science 362:1165-1170, 2018
- Koneru B, Lopez G, Farooqi A, et al. : Telomere maintenance mechanisms define clinical outcome in high-risk neuroblastoma. Cancer Res 80:2663-2675, 2020
Source: PubMed